There is an urgent requirement for the development of novel targeted
therapies to treat
breast cancer, which is the most comment type of
malignancy among women. The evasion of apoptosis is a hallmark of
cancer, and is often due to the upregulation of
inhibitor of apoptosis proteins (IAPs) in
tumor cells. Second mitochondrial‑derived activator of
caspase/direct IAP‑binding
protein with low PI is a natural IAP antagonist, which is found in the mitochondrion; this
protein has a motif, which binds to a surface groove on the baculovirus IAP repeat domains of the IAPs. In the present study, the effects of the
LCL161 Smac mimetic, a small molecule IAP antagonist, on breast cell lines was examined. The results from MTT and colony formation assays demonstrated that
LCL161 markedly inhibited the proliferation and induced the apoptosis of MDA‑MB‑231 and MCF‑7 cell lines. As determined by western blotting, cIAP1 was degraded in the
breast cancer cells, which occurred in an LCL161‑dependent manner. Upon
caspase activation,
LCL161 treatment induced necroptosis, another form of programmed cell death. The downregulation of receptor‑interacting
protein kinase‑1 via
small interfering RNA protected the cells from LCL161‑induced necroptosis. Taken together, the results of the present study showed that
LCL161 can induce multiple forms of programmed cell death in
breast cancer cells, and may thus offer promise as an
anticancer agent in diverse genotypic backgrounds.